Citadel Advisors’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $94.8K | Buy |
43,700
+16,100
| +58% | +$40K | ﹤0.01% | 12057 |
|
|
2025
Q4 | $49.7K | Buy |
27,600
+11,800
| +75% | +$24.1K | ﹤0.01% | 12038 |
|
|
2025
Q3 | $35.1K | Buy |
15,800
+5,200
| +49% | +$8.47K | ﹤0.01% | 12347 |
|
|
2025
Q2 | $15.7K | Sell |
10,600
-33,200
| -76% | -$67.9K | ﹤0.01% | 12152 |
|
|
2025
Q1 | $112K | Buy |
43,800
+38,500
| +726% | +$91.9K | ﹤0.01% | 11303 |
|
|
2024
Q4 | $9.96K | Sell |
5,300
-17,900
| -77% | -$25.3K | ﹤0.01% | 13618 |
|
|
2024
Q3 | $23.7K | Buy |
23,200
+18,600
| +404% | +$19.6K | ﹤0.01% | 12650 |
|
|
2024
Q2 | $5.38K | Sell |
4,600
-5,500
| -54% | -$6.5K | ﹤0.01% | 13407 |
|
|
2024
Q1 | $12.7K | Sell |
10,100
-13,900
| -58% | -$20.8K | ﹤0.01% | 13346 |
|
|
2023
Q4 | $42.7K | Sell |
24,000
-16,800
| -41% | -$26.1K | ﹤0.01% | 11953 |
|
|
2023
Q3 | $67.7K | Buy |
40,800
+6,300
| +18% | +$11.3K | ﹤0.01% | 11370 |
|
|
2023
Q2 | $69K | Buy |
34,500
+10,200
| +42% | +$24.3K | ﹤0.01% | 11418 |
|
|
2023
Q1 | $51K | Buy |
24,300
+7,000
| +40% | +$12.3K | ﹤0.01% | 12114 |
|
|
2022
Q4 | $23.7K | Buy |
+17,300
| New | +$19K | ﹤0.01% | 13002 |
|
|
2022
Q2 | – | Sell |
-10,900
| Closed | -$12K | – | 13814 |
|
|
2022
Q1 | $12K | Sell |
10,900
-4,800
| -31% | -$4.4K | ﹤0.01% | 13359 |
|
|
2021
Q4 | $13K | Sell |
15,700
-54,100
| -78% | -$56.7K | ﹤0.01% | 13645 |
|
|
2021
Q3 | $93K | Sell |
69,800
-61,200
| -47% | -$93K | ﹤0.01% | 12951 |
|
|
2021
Q2 | $250K | Buy |
131,000
+117,000
| +836% | +$403K | ﹤0.01% | 11698 |
|
|
2021
Q1 | $62K | Buy |
+14,000
| New | +$65.2K | ﹤0.01% | 12795 |
|
|
2017
Q2 | – | Sell |
-1,350
| Closed | -$18K | – | 7925 |
|
|
2017
Q1 | $18K | Buy |
+1,350
| New | +$12.1K | ﹤0.01% | 7274 |
|
|
2016
Q3 | – | Sell |
-1,200
| Closed | -$8K | – | 7628 |
|
|
2016
Q2 | $8K | Sell |
1,200
-2,000
| -63% | -$16K | ﹤0.01% | 6736 |
|
|
2016
Q1 | $27K | Buy |
3,200
+610
| +24% | +$5.23K | ﹤0.01% | 6398 |
|
|
2015
Q4 | $26K | Buy |
2,590
+2,350
| +979% | +$23.9K | ﹤0.01% | 7759 |
|
|
2015
Q3 | $3K | Buy |
+240
| New | +$3.81K | ﹤0.01% | 8702 |
|
|
2015
Q2 | – | Sell |
-770
| Closed | -$14K | – | 8998 |
|
|
2015
Q1 | $14K | Sell |
770
-760
| -50% | -$14.9K | ﹤0.01% | 8092 |
|
|
2014
Q4 | $28K | Buy |
1,530
+1,480
| +2,960% | +$31.8K | ﹤0.01% | 7586 |
|
|
2014
Q3 | $1K | Sell |
50
-520
| -91% | -$15K | ﹤0.01% | 8037 |
|
|
2014
Q2 | $21K | Sell |
570
-1,140
| -67% | -$46K | ﹤0.01% | 7254 |
|
|
2014
Q1 | $78K | Buy |
1,710
+90
| +6% | +$4.2K | ﹤0.01% | 6405 |
|
|
2013
Q4 | $63K | Buy |
1,620
+470
| +41% | +$19.8K | ﹤0.01% | 5910 |
|
|
2013
Q3 | $52K | Sell |
1,150
-650
| -36% | -$33.4K | ﹤0.01% | 5777 |
|
|
2013
Q2 | $88K | Buy |
+1,800
| New | +$95.5K | ﹤0.01% | 5311 |
|
Other funds holding PLX
MCO
SWP
VPM
PFS
OM
Citadel Advisors's PLX Position: Q1 2026 in Review
Citadel Advisors sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 317,628 shares — an estimated $788K sold.
Citadel Advisors first reported a position in PLX in Q2 2013 and held it in 38 quarters. The position peaked at $572K in Q4 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.
- Citadel Advisors reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 317,628 Protalix BioTherapeutics shares in Q1 2026, an estimated $788K.
- Citadel Advisors first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 38 quarters.
- Citadel Advisors's Protalix BioTherapeutics position peaked at $572K in Q4 2025.
- 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.